1Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in pre- viously treated non-small-cell lung cancer [ J ]. N Engl J Med, 2005, 353(2) :123.
2Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR21 [J]. J Clin Oncol,2006,24(24) :3831.
3Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adeno- carcinomas to gefitinib or erlotinib is associated with a second muta- tion in the EGFR kinase domain[ J]. PLoS Med,2005,2 (3) :225.
4Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 sig- naling[ J ]. Science ,2007,316 ( 5827 ) : 1039.
6Herbst RS,Johnson DH,Mininberg E,et al. Phase trial evalua-ting the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-I/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer[ J ]. J Clini Onco1,2005,23 ( 11 ) :2544.
7Uramoto H, Iwata T, Onitsuka T, et al. Epithelial -mesenchymal tran- sition in E GFR-TKI acquired resistant lung adenocarcinoma[ J ]. Anti- cancer Res,2010,30(7) :2513.
8Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor:A random- ized, double-blind phase Ill trial (ZEPHYR) [ J ]. J Clin Oncol,2012, 30(10) :1114.
9Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarci- noma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three eases [ J ]. Oncol Res, 2005,15 (2) :107.
10Schiller JH, Lee JW, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regi- mens : E2501 [ J ]. J Clin Onco1,2008,26 ( suppl 15 ) : 8014.
3Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer [J].N Engl J Med, 2005,353 (2): 123-132.
4Fishback NF,Travis WD,Moran CA,et al.Pleomorphic (spindle/giant cell) carcinoma of the lung.A clinicopathologic correlation of 78 cases[J].Cancer,1994,73(12):2936-2945.
5Perez-Soler R.Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome [J]? Oncology (Huntingt), 2003,17 (Suppl 12):23-28.
6Sequist LV,Joshi VA,Janne PA,et al.Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing[J].Oncologist, 2007,12(1):90-98.
7Gamou S,Shimosato Y,Merlino GT, et al. Methylation status of epidermal growth factor receptor gene in lung carcinoma cells [J].Jpn J Cancer Res,1988,79(9):989-995.
8Jackman DM, Yeap BY, Lindeman NI, et al. Phase Ⅱ clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for untreated advanced non-small cell cancer(NSCLS) :an analysis of life and symptom response[J]. J Clin Oncol,2007,25(7) :760-766.
9Sridhar SS, Seymou L, Shepherd FA. Inhibitors of epidermalgrowth-factor receptors a review of clinical research with a focus on non-small cell lung cancer[J]. Lancet Oncol,2003,4(7) :397- 406.
